Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PATH Malaria Vaccine Initiative (MVI) has awarded additional grants to Profectus BioSciences for the development of therapeutic and preventive vaccines against infectious diseases and cancers.
Subscribe to our email newsletter
The funds are believed to support proof-of-concept studies in non-human primates with plasmid DNA based TriGriddelivery system (TriGrid) developed by Ichor Medical Systems and recombinant vesicular stomatitis virus (rVSV) vector technologies to develop preventive malaria vaccine.
Profectus BioSciences chief scientific officer John Eldridge said the follow-on funding from MVI will help them build on their preliminary animal immunogenicity data obtained with plasmid DNA and rVSV vectors in a prime-boost vaccination regimen.
"We believe our vaccine technology can be successfully applied to a wide range of pathogens, including malaria, which has proven to be a very challenging target for vaccine development," Eldridge added.
Profectus’ two major vaccine vector platforms – pDNA and rVSV – can be sequentially administered to induce a potent and durable immune response to target pathogens.